Enovis CORP

Enovis Corporation reported a significant improvement in its financial performance for the three and six months ended July 3, 2026. Net sales for the quarter increased by 3.2% to $582.8 million, while the net loss attributable to the company narrowed substantially to $1.19 million from $36.74 million in the prior year. Operating income also turned positive, reaching $17.41 million compared to a loss in the previous year, and net cash from operating activities more than doubled to $99.0 million for the six-month period.

Enovis Corporation announced its second-quarter 2026 financial results, reporting net sales of $583 million, a 3% reported increase and 5% organic growth year-over-year. The company posted a net loss of $1 million and adjusted net earnings per diluted share of $0.90. Enovis reaffirmed its full-year 2026 financial guidance for revenue, adjusted EBITDA, adjusted EPS, and free cash flow conversion, citing improving commercial execution and a strengthening innovation pipeline despite anticipating a dynamic macroeconomic environment.

Enovis reported its second-quarter 2026 financial results, with net sales growing 3% on a reported basis and 5% organically to $583 million. The company posted a net loss of $1 million, or $0.02 per share, but achieved adjusted EBITDA of $104 million and adjusted net earnings per diluted share of $0.90. Enovis also reaffirmed its full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion, indicating confidence in its outlook despite a dynamic macroeconomic environment.

Enovis Corporation announced it will host an investor conference call and live webcast to discuss its second quarter 2026 financial results. The event is scheduled for Thursday, August 6, 2026, at 8:30 a.m. Eastern Time, following the release of an earnings press release earlier that morning. Investors can access the webcast and presentation via the company's website or participate in the call using provided dial-in details.

Enovis Corporation announced the U.S. launch of CT-RevitL™, its next-generation veterinary photobiomodulation (PBM) laser therapy system from its Companion Animal Health business. The new system, built on extensive research, offers enhanced clinical performance, greater mobility, and an intuitive treatment experience for veterinary teams. It incorporates Companion’s new COMPASS technology for precise dosing and is designed to support practice growth by expanding treatment offerings and improving client satisfaction. The system is available in the U.S. as of July 13, 2026, with international availability planned for later phases.

Enovis Corporation's stockholders approved an amendment to the 2020 Omnibus Incentive Plan at their Annual Meeting on May 19, 2026. This amendment authorizes an additional 3,650,000 shares for issuance and increases the maximum annual equity and cash compensation for Outside Directors from $350,000 to $750,000. Additionally, stockholders elected ten directors, ratified Ernst & Young LLP as the independent accounting firm for 2026, and approved the executive compensation in a non-binding advisory vote.

Enovis Corporation reported a significant improvement in its financial performance for the three months ended April 3, 2026. Net sales increased to $589.15 million, while the net loss attributable to the company substantially narrowed to $(8.76) million, or $(0.15) per diluted share, compared to a loss of $(55.97) million, or $(0.98) per share, in the prior year. The company also generated positive net cash from operating activities, totaling $23.95 million, a notable turnaround from a cash outflow in the previous year, reflecting stronger operational efficiency.

Enovis Corporation announced its first-quarter 2026 financial results, reporting net sales of $589 million, a 5% increase on a reported basis and 3% organically year-over-year. The company posted a GAAP net loss of $8 million, or $0.15 per share, but achieved adjusted EBITDA of $104 million and adjusted net earnings per diluted share of $0.89. Enovis also reaffirmed its full-year 2026 financial guidance for revenue, adjusted EBITDA, adjusted EPS, and free cash flow conversion, reflecting confidence in its innovation-led strategy despite a dynamic environment.

Enovis Corporation announced its first-quarter 2026 financial results, reporting a 5% increase in net sales to $589 million on a reported basis, with organic growth of 3%. The Reconstructive segment showed strong performance, growing 11% reported and 6% organically, while the Prevention & Recovery segment was flat reported and grew 1% organically. Despite a net loss of $8 million, the company reiterated its full-year 2026 financial guidance for revenue, adjusted EBITDA, adjusted EPS, and free cash flow conversion, citing solid execution and momentum from new product introductions.

Enovis Corporation (NYSE: ENOV) announced it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results. The event is scheduled for Thursday, May 7th, 2026, at 8:30 a.m. Eastern Time, with an earnings press release to be issued earlier that morning. This call provides a critical opportunity for institutional investors to review the company's recent performance and gain insights into management's strategic outlook. Participants can access the live webcast via the company's website or dial into the conference call using the provided details.